Study estimates how many cancer patients and survivors use complementary, alternative medicines

This study used data from a nationwide survey to estimate how many patients with cancer and cancer survivors use complementary and alternative medicines (CAMS) in addition to or instead of conventional therapies, and how many don't disclose that to their physicians.

Among about 3,100 survey participants reporting a history of cancer, 33.3 percent used CAMs in the past 12 months and the most commonly used were herbal supplements (35.8 percent), followed by other modalities that include chiropractic or osteopathic manipulation (25.4 percent); massage (14.1 percent); yoga/tai chi/qigong (7.6 percent); mantra/mindfulness/spiritual meditation (6.9 percent); special diets (2.9 percent); and acupuncture (2.0 percent). Among the 1,023 participants who reported using CAM, 288 (29.3 percent) didn't disclose that to their physicians. Many participants said they didn't disclose their CAM use because physicians didn't ask or they didn't think their physicians needed to know. Considering the high proportion of patients with cancer and cancer survivors using CAM, there needs to be more study of its use on cancer outcomes.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New blood test detects early lung damage in cancer patients on targeted therapy